Natural Products and Derivatives as Japanese encephalitis virus antivirals.
JEV
antiviral drug development
bioactive natural products
Journal
Pathogens and disease
ISSN: 2049-632X
Titre abrégé: Pathog Dis
Pays: United States
ID NLM: 101595366
Informations de publication
Date de publication:
24 Sep 2024
24 Sep 2024
Historique:
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
24
9
2024
Statut:
aheadofprint
Résumé
Japanese encephalitis virus (JEV) causes acute Japanese encephalitis (JE) in humans and reproductive disorders in pigs. There are approximately 68,000 cases of JE worldwide each year, with approximately 13,600 to 20,400 deaths. JE infections have a fatality rate of one-third, and half of the survivors experience permanent neurological sequelae. The disease is prevalent throughout the Asia-Pacific region and has the potential to spread globally. JEV poses a serious threat to human life and health, and vaccination is currently the only strategy for long-term sustainable protection against JEV infection. However, licensed JEV vaccines are not effective against all strains of JEV. To date, there are no drugs approved for clinical use, and the development of anti-JEV drugs is urgently needed. Natural products are characterized by a wide range of sources, unique structures and low prices, and this paper provides an overview of the research and development of anti-JEV bioactive natural products.
Identifiants
pubmed: 39317665
pii: 7774396
doi: 10.1093/femspd/ftae022
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of FEMS.